You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 28, 2024

Litigation Details for Galderma Laboratories L.P. v. Lupin Inc. (D. Del. 2021)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Galderma Laboratories L.P. v. Lupin Inc.
The small molecule drug covered by the patents cited in this case is ⤷  Try a Trial .

Details for Galderma Laboratories L.P. v. Lupin Inc. (D. Del. 2021)

Date Filed Document No. Description Snippet Link To Document
2023-04-07 108 Opinion - Memorandum Opinion pharmaceutically acceptable excipients. U.S. Patent No. 8,206,740 cl. 1. Sun already construed the terms…company, Sun, for infringing the same patents. Many of the patents’ terms were construed in that suit. … slowly. Galderma patented its developments. Though Galderma has several patents and dozens of claims… “It is a bedrock principle of patent law that the claims of a patent define the in- vention to which…Galderma says Lupin infringes some of its drug patents. A few years ago, Gal- derma won a lawsuit against External link to document
2023-04-07 109 Order ORDER Regarding Terms of US Patent Nos. 7,749,532; 8,206,740; 8,394,405; 8,394,406; 8,470,364; …2021 1 April 2024 1:21-cv-01710 835 Patent - Abbreviated New Drug Application(ANDA) Defendant External link to document
2023-05-10 116 Stipulation of Dismissal of Claims and Defenses Relating to U.S. Patent Nos. 8,394,405, 8,394,406, 8,470,364, and 8,709,478 by …2021 1 April 2024 1:21-cv-01710 835 Patent - Abbreviated New Drug Application(ANDA) Defendant External link to document
2023-05-11 118 of Claims and Defenses Relating to U.S. Patent Nos. 8,394,405, 8,394,406, 8,470,364, and 8,709,478. Ordered…2021 1 April 2024 1:21-cv-01710 835 Patent - Abbreviated New Drug Application(ANDA) Defendant External link to document
2023-06-08 121 Notice of Service Regarding Lupin's Infringement of U.S. Patent Nos. 7,749,532 and 8,206,740 filed by Galderma Laboratories…2021 1 April 2024 1:21-cv-01710 835 Patent - Abbreviated New Drug Application(ANDA) Defendant External link to document
2024-03-22 197 Opinion - Memorandum Opinion several patents for a once-daily doxycycline capsule. See U.S. Patent No. 7,749,532; U.S. Patent No. 8,…I reject its patent-infringement claim. I. GALDERMA SUES LUPIN FOR PATENT INFRINGEMENT…8,206,740. Together, the ’532 and ’740 patents are called the Chang patents. Tr. 13:12–14. And the commercial…claims 1 and 16 of the ’532 patent plus claims 1 and 20 of the ’740 patent. Tr. 79:11–14. Though the full…the Chang patents. Tr. 78:1–6. He began by describing the relevant practitioner for patent-infringement External link to document
2021-12-03 4 Patent/Trademark Report to Commissioner of Patents the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,749,532 B2 ;8,206,740 B2 ;8,394,405…2021 1 April 2024 1:21-cv-01710 835 Patent - Abbreviated New Drug Application(ANDA) Defendant External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.